Smith Andrew Alasdair 4

What Happened

• Andrew Alasdair Smith, Chief Operating Officer of Medicus Pharma Ltd. (MDCX), was reported as acquiring a grant/award of 50,000 shares on 2026-03-30. The transaction is recorded as a derivative award (code A) with a reported price of $0.00, giving an indicated transaction value of $0 on the Form 4 filing dated 2026-04-01.

Key Details

• Transaction date: 2026-03-30; Transaction code: A (award/grant); Price per share: $0.00; Shares acquired: 50,000.
• Filing date / Form: Form 4 filed 2026-04-01 (Accession 0000950142-26-001033).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes / special plans: No footnotes or 10b5-1 / tax-withholding items disclosed in the supplied details.
• Timeliness: Filing date is 2026-04-01 reporting the 2026-03-30 transaction; the provided data does not indicate a late filing designation.

Context

• This was an award/grant of derivative securities (commonly RSUs or restricted stock awards), not an open-market purchase or option exercise. Such awards are typically part of compensation or retention programs; vesting terms and restrictions (if any) are not shown in this summary and should be checked in the company’s proxy statements or related 8-Ks for full details.